BBO-8520

BBO-8520 is a direct small molecule covalent inhibitor targeting KRAS G12C with high oral availability. BBO-8520 has the characteristics of KRAS G12C (OFF) inhibitor and the function of blocking KRAS G12C (ON) signal. BBO-8520 inhibits cell proliferation by inhibiting KRAS G12C (ON) by binding GTP protein. BBO-8520 can block RAS-RAF1 interaction and return KRAS G12C to the inactive (OFF) state [1].

Product Specifications

CAS Number

[2893809-51-1]

UNSPSC

12352005

Target

Ras

Type

Reference compound

Related Pathways

GPCR/G Protein; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bbo-8520.html

Purity

99.90

Solubility

DMSO : ≥ 50 mg/mL

Smiles

FC1=[C@](C(C(F)(F)F)=CC2=C(N=C(N=C21)OC[C@@]34CCCN3C[C@@H](C4)F)N5[C@H](CN([C@@H](C5)C)C(C=C)=O)C)[C@]6=CC=C(F)C7=C6C(C#N)=C(N)S7

Molecular Formula

C35H33F6N7O2S

Molecular Weight

729.74

References & Citations

[1]Maciag A E, et al. Abstract ND07: BBO-8520, a first-in-class, direct inhibitor of KRASG12C (ON), locks GTP-bound KRASG12C in the state 1 conformation resulting in rapid and complete blockade of effector binding[J]. Cancer Research, 2024, 84 (7_Supplement) : ND07-ND07.|[2]Caughey B A, Strickler J H. Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies[J]. Drugs, 2024, 84 (1) : 27-44.